AbbVie’s risankizumab improves disease activity in psoriatic arthritis trial
AbbVie reports positive top-line results from two ongoing Phase III studies. Credit: AbbVie Inc.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
